IGF-1 LR3

What is IGF-1 LR3?

IGF-1 LR3 is a lab-modified version of insulin-like growth factor 1, the hormone your body makes downstream of growth hormone to drive tissue growth. The "LR3" tag describes two changes: an arginine swap at position 3 and a 13-amino-acid extension on the front end. Together they make the molecule last far longer in the body than natural IGF-1. It is popular in bodybuilding circles for muscle-growth claims. It is a research chemical with no human therapeutic approval.

How IGF-1 LR3 works

IGF-1 LR3 binds the IGF-1 receptor and switches on the same growth signals as natural IGF-1: protein synthesis and cell proliferation. The modifications matter because they cut its affinity for IGF binding proteins, the carrier proteins that normally grab IGF-1 and limit how much is free and active. With less binding-protein capture, more of the molecule stays available and its half-life stretches from minutes to many hours. IGF-1 also shares structure with insulin and can activate the insulin receptor at high levels, which is the root of its blood-sugar risk.

What the research shows

The Long-R3 modification comes out of decades-old animal and cell-culture research, where analogs that dodge IGF binding proteins were shown to be more potent than native IGF-1. That same research also documented the flip side: those low-binding IGF-1 variants produced more potent and longer-lasting drops in blood sugar than native IGF-1 in animals. That is the key safety finding. There are no human clinical trials establishing IGF-1 LR3 as safe or effective for muscle growth. The claims around it rest on mechanism and anecdote, not human outcome data.

Dosage and how it is used

There is no approved or clinically validated dose. Community protocols exist but are entirely unregulated, and the long half-life makes dosing errors more consequential, since the glucose-lowering effect can persist and accumulate over days. Treat any circulating figure as unverified.

→ How to reconstitute IGF-1 LR3: calculator, units to draw & storage

Side effects and safety

The most immediate risk is hypoglycemia. Because IGF-1 LR3 can act on the insulin receptor and stays active for many hours, a dose can drop blood sugar in a way that lingers, and repeated dosing can build up. There is also a well-reasoned theoretical concern about promoting the growth of existing tumors, given that IGF-1 signaling drives cell proliferation.

• Real hypoglycemia risk that can persist for many hours because of the long half-life.
• Theoretical cancer-promotion concern from proliferative IGF-1 signaling.
• No human trials; research chemical, not FDA-approved. Verify current legal status independently.

Frequently asked questions

References

• Tomas FM et al. Superior potency of infused IGF-I analogues which bind poorly to IGF-binding proteins is maintained when administered by injection. Journal of Endocrinology, 1996.
• Tomas FM et al. IGF-I variants which bind poorly to IGF-binding proteins show more potent and prolonged hypoglycaemic action than native IGF-I in pigs and marmoset monkeys. Journal of Endocrinology, 1997.